October 2012
Reactions Weekly;10/6/2012, Issue 1422, p16
Case Study
The article describes the case of a 22-year-old man with cholestatic hepatitis A virus who developed DRESS syndrome after receiving oseltamivir, metronidazole and cefotaxime.


Related Articles

  • Government will spend another £49m on Tamiflu. Torjesen, Ingrid // BMJ: British Medical Journal;4/19/2014, Vol. 348 Issue 7954, p3 

    The article reports the move by the British government as of mid-April 2014 to advance its plan to spend 49 million pounds to replace inventories of oseltamivir (Tamiflu) that are due to expire. It claims that the results of the Cochrane Collaboration review was considered in making the...

  • Treatment for Trichomonas vaginalis.  // Modern Medicine;Aug94, Vol. 62 Issue 8, p26 

    Reports on the availability of the drug metronidazole in capsule form.

  • Study claiming Tamiflu saved lives was "flawed". Kmietowicz, Zosia // BMJ: British Medical Journal;3/22/2014, Vol. 348 Issue 7950, p1 

    The article discusses research on Tamiflu conducted by Mark Jones, a statistician at the University of Queensland in Brisbane. The research claims that a study that found that neuraminidase inhibitor Tamilflu reduced the risk of deaths among adults treated in hospital during the 2009-10 H1N1 flu...

  • No place for antiviral drug distribution in a flu pandemic. Saunders, Patrick J.; Middleton, John // BMJ: British Medical Journal;5/3/2014, Vol. 348 Issue 7956, p15 

    A letter to the editor is presented in response to the article "Oseltamivir for Influenza in Adults and Children: Systematic Review of Clinical Study Reports and Summary of Regulatory Comments," by T. Jefferson and colleagues in the 2014 issue.

  • Oseltamivir/warfarin interaction.  // Reactions Weekly;3/17/2012, Issue 1393, p32 

    The article describes the clinical cases of seven patients who developed increased INR while under warfarin and oseltamivir treatment regimens.

  • Cochrane questions effectiveness of Tamiflu. Torjesen, Ingrid // BMJ: British Medical Journal;4/12/2014, Vol. 348 Issue 7953, p1 

    The article discusses the Cochrane Collaboration's systematic review of the neuraminidase inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza) manufactured respectively by Roche and GlaxoSmithKline (GSK). Topics addressed include the money allegedly wasted by the Department of Health for...

  • Oseltamivir: the real world data. Freemantle, Nick; Shallcross, L. J.; Kyte, D.; Rader, T.; Calvert, M. J. // BMJ: British Medical Journal;4/12/2014, Vol. 348 Issue 7953, p22 

    The article discusses observational evidence on the effects of oseltamivir on influenza treatment. Topics addressed include the advantages of observational studies over randomized clinical trials, oseltamivir's effect on mortality, and the use of oseltamivir to treat children with influenza....

  • Neuraminidase inhibitors for influenza. Krumholz, Harlan M. // BMJ: British Medical Journal;4/12/2014, Vol. 348 Issue 7953, p8 

    The author discusses how the Cochrane reviews on the benefits and harms of the neuraminidase inhibitors oseltamivir and zanamivir marks the first time that all pertinent data from manufacturers' clinical trials were made publicly available. Topics addressed include the medical industry's...

  • Double dose oseltamivir for severe influenza-does it help? Barr, Ian G.; Hurt, Aeron C. // BMJ: British Medical Journal;6/8/2013, Vol. 346 Issue 7911, p10 

    The author reflects on the effect of double dose of oseltamivir drug for severe influenza described by the South East Asian Infectious Disease Clinical Research Network (SEAICRN). He states that the neuraminidase inhibitors are more effective for cases of severe influenza such as those caused by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics